Linearis Unveils AI-Integrated Metabolomics Platform

Linearis has launched a high-throughput metabolomics platform in Quebec City, announced in a press release. This new platform integrates artificial intelligence to support life sciences projects, aiming to accelerate benefits for patients.

The platform is equipped with advanced technology for the rapid and precise analysis of approximately 1,300 metabolic biomarkers. This capability allows Linearis to offer tailored services to biobanks, clinical research groups, and biopharmaceutical companies. The focus is on identifying elements linked to metabolic diseases such as cancer, diabetes, and antimicrobial resistance, with the goal of enhancing prevention, screening, treatment monitoring, and drug discovery.

According to Alexandre Le Bouthillier, CEO of Linearis, the launch of this laboratory, combined with their investment fund, marks a significant step in establishing a biohub at the intersection of AI and life sciences. This integrated model is designed to better support the ecosystem and accelerate the transformation of scientific discoveries into real-world solutions for patients.